Document:

Prepared by R.R. Donnelley Financial -- Stock Option Agreement

 Exhibit 10.84 
  
 GRANT OF STOCK OPTION 
  
 Edward V. Fritzky, Amgen Inc. Stock
Optionee: 
  
 Amgen Inc., a Delaware corporation (the “Company”), pursuant to its Amended and Restated 1991
Equity Incentive Plan (the “Plan”) has on July 15, 2002 (the “Grant Date”), granted to you, the optionee named above, an option to purchase 450,000 shares (the “Option Shares”) of the $.0001 par value common stock of
the Company (“Common Stock”) pursuant to the terms hereof. This option is not intended to qualify and will not be treated as an “incentive stock option” within the meaning of Section 422 of the Internal Revenue Code of 1986, as
amended (the “Code”). 
  
 The provisions of your option are as follows: 
  
 I.  Subject to Section V and the limitations contained herein, this option shall be exercisable as follows:

  
 
	 # Option Shares
 
	  	 Date Exercisable
 

	 150,000
 	  	 Grant Date
 
	 150,000
 	  	 First anniversary of Grant Date
 
	 150,000
 	  	 Second anniversary of Grant Date
 

 
  
 Notwithstanding anything herein to the contrary, such vesting schedule may be accelerated
by the Company in its sole discretion at any time during the term of this option. In addition, vesting may be suspended during a leave of absence as provided from time to time according to Company policies and practices. 
  
 II.  (1)    The per share exercise price of this option is $31.07, being not less
than the fair market value of the Common Stock on the date of grant of this option. 
  
 (2)    To the extent permitted by applicable statutes and regulations, payment of the exercise price per share is due in full in cash or check upon exercise of all or any part of each installment which has become
exercisable by you. However, if at the time of exercise, the Company’s Common Stock is publicly traded and quoted regularly in the Wall Street Journal, payment of the exercise price may be made by delivery of already-owned shares of
Common Stock of a value equal to the exercise price of the shares of Common Stock for which this option is being exercised. The already-owned shares must have been owned by you for the period required to avoid a charge to the Company’s reported
earnings and owned free and clear of any liens, claims, encumbrances or security interests. Payment may also be made by a combination of cash and already-owned Common Stock. 
 

 1 

  
 III.  Notwithstanding anything to the contrary
contained herein, this option may not be exercised unless the shares issuable upon exercise of this option are then registered under the Securities Act of 1933, as amended (the “Act”), or, if such shares are not then so registered, the
Company has determined that such exercise and issuance would be exempt from the registration requirements of the Act. 
  
 IV.  The term of this option commences on the Grant Date and, unless sooner terminated as set forth in the Plan, terminates on the fifth anniversary of the Grant Date (the “Expiration Date”).

  
 V.  If, during the Employment Period: 
  
 (1)  Your employment is terminated by the Company for Cause, or by you without Good Reason, then any portion of
the Option Shares which is unvested as of the Termination Date shall be forfeited and the option shall remain exercisable until the Expiration Date with respect to any vested portion of the option; or 
  
 (2)  Your employment is terminated (a) by you for Good Reason or (b) by the Company other than by reason of
death, disability pursuant to Section 13 of the Employment Agreement (as defined below), or Cause, then immediately prior to the Termination Date the option shall accelerate and be exercisable in full and the option shall remain exercisable until
the Expiration Date; or 
  
 (3)  Your employment is terminated due to your death, then
immediately prior to the Termination Date, the option shall accelerate and be exercisable in full and the option remain exercisable until the Expiration Date; or 
  
 (4)  Your employment is terminated on account of your disability (as set forth in Section 10(a) of the Plan) in accordance with Section 13 of the
Employment Agreement (as defined below), then immediately prior to the Termination Date, the option shall accelerate and be exercisable in full and the option shall remain exercisable until the Expiration Date. 
  
 For purposes of this Section V, the terms “Employment Period”, “Cause”, “Good Reason”, and
“Termination Date” shall have the meanings assigned to such terms in the Employment Agreement dated as of July 15, 2002, between the Company and you (as amended from time to time, the “Employment Agreement”). For purposes of this
Section V, “your employment is terminated” shall mean the last date you are either an employee of the Company or an Affiliate or engaged as a consultant or director to the Company or an Affiliate. 
  
 VI.  (1)    To the extent specified above, this option may be exercised by delivering a
Notice of Exercise of Stock Option form, together with the exercise price to the Secretary of the Company, or to such other person as the Company may designate, during regular business hours, together with such additional documents as the Company
may then 
 

 2 

  
 require pursuant to subparagraph 5(f) of the Plan. 
  
 (2)  As a condition to the issuance of shares upon the exercise of this option, the Company may require you to
enter an arrangement providing for the payment by you to the Company of any tax withholding obligation of the Company arising by reason of: (1) the exercise of this option; (2) the lapse of any substantial risk of forfeiture of which the shares are
subject at the time of exercise; or (3) the disposition of shares acquired upon such exercise. 
  
 VII.  This option is not transferable, except by will or the laws of descent and distribution, and is exercisable during your life only by you except as set forth below: 
  

(1)  If you have named a Trust (as defined in the Plan) as beneficiary of this option, this option may be exercised by the Trust after your
death; and 
  
 (2)  All or a portion of your option may be transferred to an Alternate
Payee (as defined in the Plan) if required by the terms of a QDRO (as defined in the Plan), as further described in the Plan. 
  
 VIII.  This option is not an employment or service contract and nothing in this option shall be deemed to create in any way whatsoever any obligation on your part to continue in the employ or
service of the Company, or of the Company to continue your employment or service with the Company. 
  
 IX.  Any notices provided for in this option or the Plan shall be given in writing and shall be deemed effectively given upon receipt or, in the case of notices delivered by the Company to you, five (5) days after deposit
in the United States mail, postage prepaid, addressed to you at the address specified in the Option Notice or at such other address as you hereafter designate by written notice to the Company. 
  

X.  This option is subject to all the provisions of the Plan and its provisions are hereby made a part of this option, including without
limitation the provisions of paragraph 5 of the Plan relating to option provisions, and is further subject to all interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the
event of any conflict between the provisions of this option (including the Option Notice) and those of the Plan, the provisions of the Plan shall control. 
  
  

	 Very truly yours,

  
 AMGEN INC.
 
	 
	 By:
 	 	 /S/    STEVEN M. ODRE
 

	  	 	 Duly authorized on behalf
of the Board of Directors
 

 
 

 3Prepared by R.R. Donnelley Financial -- Agreement between Amgen and Dr. Douglas Williams

 Exhibit 10.85 
  
 July 15, 2002 
  
 Dr. Douglas E. Williams, Ph.D.

  
 Dear Doug: 
  
 It is our sincere pleasure to welcome you to Amgen. This letter summarizes the terms of your continuing employment. You will continue to be employed as a full time staff
member. Your position will be Senior Vice President, Research, Amgen salary grade 37. Your base salary will be $37,500.00 per month. 
  
 In addition, a stock option for you to purchase 125,000 shares of Common Stock at a price equal to 100% of the fair market value on the date of close has been approved by the Amgen’s Compensation Committee. All of these
shares will vest at the following rate: Forty thousand (40,000) shares shall vest on the date which is two years and one day after the date of grant, forty thousand (40,000) shares shall vest on the date which is three years and one day after the
date of grant, and forty five thousand (45,000) shares shall vest on the date which is four years and one day after the date of grant, provided you are still employed on those dates and the options will expire seven years from the date of grant.

  
 In addition, you will receive a grant of restricted stock for 15,000 shares. All of the shares will vest at the
following rate: Seven thousand five hundred (7,500) shares will vest and the restrictions thereon will lapse on the date which is two years and one day after the date of grant, and seven thousand five hundred (7,500) shares will vest and the
restrictions thereon will lapse on the date which is three years and one day after the date of grant. Should you terminate employment with Amgen prior to the vesting dates, unvested shares will be repurchased by Amgen at the per share ($0.01)
purchase price paid by you for such shares. Amgen will hold these stock certificates until they vest. 
  
 Immunex
will pay a prorated 2002 incentive payment through close. Effective as of the date of close, you will be eligible to participate in Amgen’s Management Incentive Plan (MIP) with a target award of 65% of eligible base pay. Through December 31,
2005, your incentive target will be the higher of the incentive target applicable to your Amgen grade or your current Immunex incentive target. In order to be eligible to receive an incentive payment under MIP, you must be an active employee on
December 31 of the plan year. 
  
 You will also be eligible to participate in the Amgen Deferred Compensation Plan
(the “DCP”). The DCP is a non-qualified executive benefit plan that enables staff at grade levels 30 and above to defer, on a pre-tax basis, a portion of their annual pay, including MIP payments. Information about the DCP and the necessary
enrollment forms were provided to you at briefings the week of July 8th. They are also available from the
HR Service Center (extension 56100). Should you decide to accept this offer of employment and participate in the DCP for the remainder of 2002 (base and/or bonus), you must complete the enrollment materials and return them in the envelope provided
to Clark/Bardes no later than July 31, 2002. Enrollment for the 2003 plan year will be conducted during November 2002. Enrollment materials received after July 31, 2002 will not be accepted. 
  
 Amgen and Immunex have designed a total benefits program for the combined company which is very competitive. Best practices from both companies have been incorporated to
produce what we believe is an industry leading benefit package. Informational briefings will be available to you, and a benefits summary brochure is concurrently being made available. We anticipate that the combined benefit offering will be
effective January 1, 2003. 
 

 1 

  
 Douglas E. Williams 
 July 15,
2002 
 Page 2 
  
 By signing this letter, you
understand and agree that your employment with Immunex and Amgen (collectively, “the Company”) is at-will. Therefore, your employment can terminate, with or without cause, and with or without notice, at any time, at your option or the
Company’s option, and the Company can terminate or change all other terms and conditions of your employment, with or without cause, and with or without notice, at any time. This at-will relationship will remain in effect throughout your
employment with the Company or any of its subsidiaries or affiliates. This letter constitutes the entire agreement, arrangement and understanding between you and the Company on the nature and terms of your employment with the Company. This letter
supersedes any prior or contemporaneous agreement, arrangement or understanding on this subject matter. By executing this letter as provided below, you expressly acknowledge the termination of any such prior agreement, arrangement or
understanding. (However, nothing in this paragraph shall limit or in any other way affect any Mutual Agreement to Arbitrate Claims—or amendments thereto—that you have entered into with the Company.) Also, by your execution of
this letter, you affirm that no one has made any written or verbal statement that contradicts the provisions of this letter. The at-will nature of your employment, as set forth in this paragraph, can be modified only by a written agreement signed by
both Amgen’s Senior Vice President of Human Resources and you which expressly alters it. This at-will relationship may not be modified by any oral or implied agreement or by any Company policies, practices or patterns of conduct. Please note
that this letter does not alter or waive your potential benefits, if any, under the Immunex Corporation Retention Plan, Immunex Corporation Leadership Continuity Plan, Immunex Corporation Employee Severance Plan, and/or the Purchase Agreement among
American Homes Products Corporation (now named Wyeth)/AHP Subsidiary Holding Corporation and Immunex Corporation and the Severance Agreement by and between the Company and Douglas E. Williams dated December 16, 2001. 
  
 We are excited to have you join Amgen and are enthusiastic about the contribution that you can make. We also believe that Amgen can
provide you with attractive opportunities for professional achievement and growth. As a precondition to employment with Amgen, it is necessary for you to (1) sign and date the enclosed copy of this letter, (2) complete, sign and date the attached
Amended and Restated Proprietary Information and Inventions Agreement and Data Request and Transfer Form, and (3) return all three fully-executed documents to Attn: HR Service Center, 51 University Street, Seattle WA 98101 no later than the close of
business on the second business day following receipt of this assignment letter. Please retain one original offer letter for your records. If you do not return fully executed copies of the foregoing documents by the close of business on the second
business day following receipt of this assignment letter, Amgen will consider you to have voluntarily resigned your employment (in which case you would not be eligible to receive severance benefits). If you have any questions regarding this offer,
please contact your HR manager, the Amgen HR representative who is on site, or HR On-Call in Thousand Oaks at (800) 9-AMGEN-9, extension 71111. 
  
 Sincerely, 
  
 Roger M. Perlmutter 
 Executive Vice President, Research & Development 
  
 RMP:ma 
 Enclosures 
  
 
	 /s/    DOUGLAS E. WILLIAMS
 
Signature of Acceptance
 	  	 7/15/02

 
Date
 

 
 

 2 

 Douglas E. Williams 
 July 15, 2002 
 Page 3 
  
  
 ATTACHMENT 1

 Page 1 of 1 
  
 As
a precondition to employment with Amgen you are required to: 
  

	 	A)
	 
	Sign, date and return the enclosed copy of this letter. 
 

  

	 	B)
	 
	Complete, date and sign the Amended and Restated Proprietary Information and Inventions Agreement and return it with your signed assignment letter.

 

  

	 	C)
	 
	Complete, sign and date all sections of the enclosed Data Request and Transfer Form and return it with your signed assignment letter. 

 

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]